U.S. markets closed

IVERIC bio, Inc. (ISEE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
13.25+0.44 (+3.43%)
At close: 04:00PM EDT
13.25 0.00 (0.00%)
After hours: 04:32PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close12.81
Bid13.25 x 3000
Ask14.74 x 4000
Day's Range12.81 - 13.37
52 Week Range8.37 - 19.34
Avg. Volume2,111,930
Market Cap1.565B
Beta (5Y Monthly)1.52
PE Ratio (TTM)N/A
EPS (TTM)-1.13
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.08
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ISEE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • IVERIC bio, Inc.
    Technical Assessment: Neutral in the Intermediate-TermCrude oil (WTI) continues to correct, pulling gasoline prices down with it. Since peaking at $123.68 on an intraday basis June 14, crude has been in a consistent downward-sloping channel. On Wednesday, WTI closed near $90.80/barrel, its lowest close since February18 and down 26% from its most-recent closing high of $122.11. More importantly, crude oil, at least for a day, has broken the bottom of its range (in the $93 region) going back to March. We need to see a few more days to confirm a major breakdown.
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • InvestorPlace

    7 Cheap Biotech Stocks to Buy Now

    Biopharmaceutical companies have been struggling since 2021 and that narrative isn’t immediately changing. However, not every firm deserves this fate. In fact, investors can find great opportunities with “cheap” biotech stocks to buy now. There are many reasons for investor pessimism that could soon ease. For instance, drug innovation has stagnated in 2022. Companies also haven’t been able to announce as many positive clinical readouts to build confidence. These both could change in a jiffy if a

  • Business Wire

    Iveric Bio to Present at the Wedbush PacGrow Healthcare Conference 2022

    PARSIPPANY, N.J., August 03, 2022--Iveric Bio announced the Company will participate in a fireside chat at the Wedbush PacGrow Healthcare Conference 2022 on Tuesday, August 9, 2022.

  • Business Wire

    Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    PARSIPPANY, N.J., August 02, 2022--Iveric Bio granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive employees.